Show simple item record

dc.contributor.authorFarhadfar, N.
dc.contributor.authorDias, A.
dc.contributor.authorWang, T.
dc.contributor.authorFretham, C.
dc.contributor.authorChhabra, S.
dc.contributor.authorMurthy, H.S.
dc.contributor.authorBroglie, L.
dc.contributor.authorD'Souza, A.
dc.contributor.authorGadalla, S.M.
dc.contributor.authorGale, R.P.
dc.contributor.authorHashmi, S.
dc.contributor.authorAl-Homsi, A.S.
dc.contributor.authorHildebrandt, G.C.
dc.contributor.authorHematti, P.
dc.contributor.authorRizzieri, D.
dc.contributor.authorChee, L.
dc.contributor.authorLazarus, H.M.
dc.contributor.authorBredeson, C.
dc.contributor.authorJaimes, E.A.
dc.contributor.authorBeitinjaneh, A.
dc.contributor.authorBashey, A.
dc.contributor.authorPrestidge, T.
dc.contributor.authorKrem, M.M.
dc.contributor.authorMarks, D.I.
dc.contributor.authorBenoit, S.
dc.contributor.authorYared, J.A.
dc.contributor.authorNishihori, T.
dc.contributor.authorOlsson, R.F.
dc.contributor.authorFreytes, C.O.
dc.contributor.authorStadtmauer, E.
dc.contributor.authorSavani, B.N.
dc.contributor.authorSorror, M.L.
dc.contributor.authorGanguly, S.
dc.contributor.authorWingard, J.R.
dc.contributor.authorPasquini, M.
dc.date.accessioned2021-04-12T13:11:10Z
dc.date.available2021-04-12T13:11:10Z
dc.date.issued2021-02-26
dc.identifier.urihttp://hdl.handle.net/10713/15159
dc.description.abstractRenal dysfunction is a recognized risk factor for mortality after allogeneic hematopoietic cell transplantation (alloHCT), yet our understanding of the effect of different levels of renal dysfunction at time of transplantation on outcomes remains limited. This study explores the impact of different degrees of renal dysfunction on HCT outcomes and examines whether the utilization of incremental degrees of renal dysfunction based on estimated glomerular filtration rate (eGFR) improve the predictability of the hematopoietic cell transplantation comorbidity index (HCT-CI). The study population included 2 cohorts: cohort 1, comprising patients age ?40 years who underwent alloHCT for treatment of hematologic malignancies between 2008 and 2016 (n = 13,505; cohort selected given a very low incidence of renal dysfunction in individuals age <40 years), and cohort 2, comprising patients on dialysis at the time of HCT (n = 46). eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method. The patients in cohort 1 were assigned into 4 categories - eGFR ?90 mL/min (n = 7062), eGFR 60 to 89 mL/min (n = 5264), eGFR 45 to 59 mL/min (n = 897), and eGFR <45 mL/min (n=282) - to assess the impact of degree of renal dysfunction on transplantation outcomes. Transplantation outcomes in patients on dialysis at the time of alloHCT were analyzed separately. eGFR <60 mL/min was associated with an increased risk for nonrelapse mortality (NRM) and requirement for dialysis post-HCT. Compared with the eGFR ?90 group, the hazard ratio (HR) for NRM was 1.46 (P =.0001) for the eGFR 45 to 59 mL/min group and 1.74 (P =.004) for the eGFR <45 mL/min group. Compared with the eGFR ?90 mL/min group, the eGFR 45 to 59 mL/min group (HR, 2.45; P <.0001) and the eGFR <45 mL/min group (HR, 3.09; P <.0001) had a higher risk of renal failure necessitating dialysis after alloHCT. In addition, eGFR <45 mL/min was associated with an increased overall mortality (HR, 1.63; P <.0001). An eGFR-based revised HCT-CI was also developed and shown to be predictive of overall survival (OS) and NRM, with predictive performance similar to the original HCT-CI. Among 46 patients on dialysis at alloHCT, the 1-year probability of OS was 20%, and that of NRM was 67%. The degree of pretransplantation renal dysfunction is an independent predictor of OS, NRM, and probability of needing dialysis after alloHCT. An eGFR-based HCT-CI is a validated index for predicting outcomes in adults with hematologic malignancies undergoing alloHCT. The outcomes of alloHCT recipients on dialysis are dismal; therefore, one should strongly weigh the significant risks of being on hemodialysis as a factor in determining alloHCT candidacy.en_US
dc.description.urihttps://doi.org/10.1016/j.jtct.2021.02.030en_US
dc.language.isoen_USen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofTransplantation and Cellular Therapy
dc.subjectAllogeneic transplantationen_US
dc.subjectDialysisen_US
dc.subjectHCT-CIen_US
dc.subjectRenal dysfunctionen_US
dc.titleImpact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantationen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jtct.2021.02.030


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record